New antibody drug shows early promise for advanced cancer patients
NCT ID NCT07554196
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This early-stage study tested a new antibody drug called HH-101 in 12 adults with advanced solid tumors that had not responded to other treatments. The main goal was to check if the drug is safe and to find the right dose. Researchers monitored side effects and looked for any signs that the drug might shrink tumors, but this is not a cure and ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.